Evidence map›Paper›PMID 37297936›Full record

ArticleJournal of clinical medicine2023

Negative Prognostic Impact of Mineralocorticoid Receptor Antagonist in Elderly Patients Receiving TAVR.

Teruhiko Imamura, Nikhil Narang, Hiroshi Onoda, Shuhei Tanaka, Ryuichi Ushijima, Mitsuo Sobajima, Nobuyuki Fukuda, Hiroshi Ueno, Koichiro Kinugawa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Teruhiko ImamuraThe Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-7294-7637
Nikhil NarangAdvocate Christ Medical Center, Oak Lawn, IL 60453, USA.
Hiroshi OnodaThe Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
Shuhei TanakaThe Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0001-7551-3431
Ryuichi UshijimaThe Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-4543-596X
Mitsuo SobajimaThe Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
Nobuyuki FukudaThe Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
Hiroshi UenoThe Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0001-9747-2511
Koichiro KinugawaThe Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
University of Toyama · JPAdvocate Christ Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

methodsConsecutive patients who received TAVR at our institute between 2015 and 2022 were considered for inclusion. Propensity score matching analysis was performed to match pre-procedural baseline characteristics between those with and without MRA. The prognostic impact of MRA use on the composite primary endpoint consisting of all-cause death and heart failure during the 2-year observational period following index discharge was evaluated.

resultsAmong 352 patients who received TAVR, 112 patients (median 86 years, 31 men) were included, consisting of baseline-matched 56 patients with MRA and 56 patients without MRA. Following TAVR, patients with MRA had more impaired renal function compared with no MRA group. Following index discharge, serum potassium tended to increase, and renal function tended to decline in patients with MRA. Patients with MRA had a higher cumulative incidence of the primary endpoints during a two-year observational period (30% versus 8%,

conclusionsRoutine prescription of MRA might not be recommended in elderly patients with severe aortic stenosis receiving TAVR, given its negative prognostic impact. Optimal patient selection for MRA administration in this cohort needs further study.

Indexed as

aortic valve diseasecongestionheart failurehemodynamics

Identifiers

PMID37297936
PMCPMC10253895
OpenAlexW4378715806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.